Adherence to Janus Kinase Inhibitors Among Older Adults with Rheumatoid Arthritis Initiating New Treatment

Janus Kinase Inhibitors (JAKIs) are a recent advancement in Rheumatoid Arthritis (RA) treatment, offering an effective oral therapy option. However, adherence to JAKIs in RA patients is suboptimal compared to injectable options. Additionally, there is limited research on adherence to JAKIs among older adults in the United States. The study in question focused on examining JAKIs adherence in older RA patients enrolled in Medicare and identifying factors contributing to poor adherence.https://egrove.olemiss.edu/pharm_annual_posters_2024/1006/thumbnail.jp